CareDx Stockholders Approve Key Proposals at Annual Meeting

The latest announcement is out from CareDx ( (CDNA) ).

On June 12, 2025, CareDx, Inc. held its Annual Meeting of Stockholders where several key proposals were voted upon. The stockholders approved the election of two Class II directors, Fred E. Cohen and R. Bryan Riggsbee, the ratification of Deloitte & Touche LLP as the independent accounting firm, the executive compensation on an advisory basis, and an amendment to the 2024 Equity Incentive Plan.

The most recent analyst rating on (CDNA) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on CareDx stock, see the CDNA Stock Forecast page.

Spark’s Take on CDNA Stock

According to Spark, TipRanks’ AI Analyst, CDNA is a Outperform.

CareDx’s overall stock score is driven by strong financial performance and a positive earnings outlook, supported by promising corporate strategies like stock repurchases. Technical analysis presents mixed signals, and reasonable valuation supports a solid investment case.

To see Spark’s full report on CDNA stock, click here.

More about CareDx

Average Trading Volume: 1,022,775

Technical Sentiment Signal: Buy

Current Market Cap: $1.11B

See more data about CDNA stock on TipRanks’ Stock Analysis page.